RxDoctor Payments Data

Fallon Schloemer, DO

Neurology · Milwaukee, WINPI 1548585649

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $40,038 of the $47,583 with a category attached, or 84.1%. AbbVie accounts for 69.2% of it on its own, with 3 other manufacturers making up the rest. Among neurology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,583in general payments, 2019–2025

Across 74 payments — averaging $643.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$33K
  • Lilly USA, LLC$15K
  • Amgen$75
  • Impel Pharmaceuticals Inc.$33

What the payments were for

  • Consulting fees$3,5637%
  • Speaking & faculty fees$40,03884%
  • Travel & lodging$2,3225%
  • Food & beverage$1,6523%
  • Education$80%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)49$32,907
Lilly USA, LLC21$14,568
Amgen3$75
Impel Pharmaceuticals Inc.1$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,583 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$10,964
Medicare patients
69
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm244$211,071
QuliptaAtogepant85$139,370
Nurtec OdtRimegepant Sulfate62$121,998
UbrelvyUbrogepant87$108,085
Aimovig AutoinjectorErenumab-Aooe51$76,150
Ajovy AutoinjectorFremanezumab-Vfrm39$41,375
Ajovy SyringeFremanezumab-Vfrm15$17,123
Diclofenac Potassium16$9,715
ReyvowLasmiditan Succinate14$9,185
Sumatriptan Succinate98$7,676
TegretolCarbamazepine11$3,856
RizatriptanRizatriptan Benzoate115$3,564
Eletriptan HbrEletriptan Hydrobromide21$3,112
Tizanidine Hcl126$2,214
Naratriptan Hcl23$1,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$32,907$247,455172 claims
Lilly USA, LLCReyvow$14,568$9,18514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Wisconsin.

Other neurology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →